Merck (MRK) Advances While Market Declines: Some Information for Investors

17.04.24 23:50 Uhr

Werte in diesem Artikel
Aktien

120,80 EUR 0,60 EUR 0,50%

166,40 EUR -1,15 EUR -0,69%

Indizes

PKT PKT

PKT PKT

1.621,6 PKT 4,3 PKT 0,27%

18.769,0 PKT 64,5 PKT 0,35%

7.225,6 PKT 24,8 PKT 0,34%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

192,6 PKT -0,2 PKT -0,11%

39.836,2 PKT -167,4 PKT -0,42%

525,5 PKT 0,7 PKT 0,13%

10.011,8 PKT 30,0 PKT 0,30%

18.740,5 PKT 24,5 PKT 0,13%

18.757,5 PKT 41,1 PKT 0,22%

15.554,5 PKT 56,1 PKT 0,36%

7.397,7 PKT 23,4 PKT 0,32%

16.939,1 PKT 102,3 PKT 0,61%

2.528,2 PKT 5,6 PKT 0,22%

5.312,2 PKT 8,9 PKT 0,17%

18.738,9 PKT 13,0 PKT 0,07%

The most recent trading session ended with Merck (MRK) standing at $125.37, reflecting a +0.25% shift from the previouse trading day's closing. The stock's change was more than the S&P 500's daily loss of 0.58%. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 1.15%.Shares of the pharmaceutical company witnessed a gain of 2.34% over the previous month, beating the performance of the Medical sector with its loss of 6.07% and the S&P 500's loss of 1.09%.Investors will be eagerly watching for the performance of Merck in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 25, 2024. The company is predicted to post an EPS of $2.01, indicating a 43.57% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $15.34 billion, indicating a 5.85% increase compared to the same quarter of the previous year.For the full year, the Zacks Consensus Estimates are projecting earnings of $8.57 per share and revenue of $64 billion, which would represent changes of +467.55% and +6.46%, respectively, from the prior year.Any recent changes to analyst estimates for Merck should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.1% lower. Right now, Merck possesses a Zacks Rank of #3 (Hold).Digging into valuation, Merck currently has a Forward P/E ratio of 14.59. This represents a premium compared to its industry's average Forward P/E of 13.56.We can additionally observe that MRK currently boasts a PEG ratio of 1.62. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Large Cap Pharmaceuticals industry had an average PEG ratio of 1.67.The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 195, placing it within the bottom 23% of over 250 industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.Free Report – The Bitcoin Profit PhenomenonZacks Investment Research has released a Special Report to help you pursue massive profits from the world’s first and largest decentralized form of money.No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%.Zacks predicts another significant surge. Click below for Bitcoin: A Tumultuous Yet Resilient History.Download Now – Today It’s FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Merck

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Merck

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Merck KGaA

Analysen zu Merck KGaA

DatumRatingAnalyst
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
07.05.2024Merck OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
16.05.2024Merck KaufenDZ BANK
16.05.2024Merck OverweightBarclays Capital
15.05.2024Merck BuyUBS AG
08.05.2024Merck BuyUBS AG
07.05.2024Merck OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
06.12.2023Merck HaltenDZ BANK
27.11.2023Merck HaltenDZ BANK
27.04.2023Merck HaltenDZ BANK
10.11.2022Merck NeutralUBS AG
05.08.2022Merck HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"